ABSTRACT
OBJECTIVES: Improving immune status of people living with HIV through antiretroviral therapy (ART) may also reduce shedding of other viruses in semen. We characterized the seminal fluid virome of men with HIV and tested potential associations between viruses present and CD4 T-cell count, HIV viremia, and antiretroviral therapy (ART) status. DESIGN AND METHODS: Metagenomics was used to enrich and sequence viral nucleic acids from the seminal fluid of 55 semen samples from 42 men living with HIV from San Francisco with a median age of 33 (IQR, 28.7-45) and median CD4 T-cell counts of 837âcells/µl (IQR, 258-1571âcells/µl). All samples were collected between 2005 and 2015, and ART status was ascertained from medical records. RESULTS: Anelloviruses, cytomegalovirus (CMV), and multiple genotypes of human papillomaviruses were detected. Participants shed from 0 to 4 distinct human viruses. Longitudinally collected seminal fluid samples showed changes in the viruses shed. Viruses were more frequently shed by individuals with detectable HIV viremia (43.7 vs. 15.4%, Pâ=â0.042). A trend was seen for increased shedding by individuals who were not on ART (42.8 vs. 17.8%, Pâ=â0.082) or with CD4 T-cell count less than 350âcells/µl (35.3 vs. 20%, Pâ=â0.27). CONCLUSION: Seminal fluid from men with HIV from San Francisco contains nucleic acids from three different DNA viral families. A greater number of viruses, particularly CMV, were shed by participants with detectable HIV viremia (18.9 vs. 0%, Pâ=â0.022). Control of viremia through ART may lower shedding of other viruses in semen in addition to HIV.
Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/isolation & purification , Semen/virology , Virome , Anelloviridae/isolation & purification , Antiretroviral Therapy, Highly Active , Blood/virology , CD4 Lymphocyte Count , Cytomegalovirus/isolation & purification , DNA, Viral/genetics , DNA, Viral/isolation & purification , Genotype , HIV Infections/diagnosis , HIV-1/genetics , Humans , Male , Metagenomics , RNA, Viral , San Francisco , Virus SheddingABSTRACT
Non-biological synthetic oligomers can serve as ligands for antibodies. We hypothesized that a random combinatorial library of synthetic poly-N-substituted glycine oligomers, or peptoids, could represent a random "shape library" in antigen space, and that some of these peptoids would be recognized by the antigen-binding pocket of disease-specific antibodies. We synthesized and screened a one bead one compound combinatorial library of peptoids, in which each bead displayed an 8-mer peptoid with ten possible different amines at each position (10(8) theoretical variants). By screening one million peptoid/beads we found 112 (approximately 1 in 10,000) that preferentially bound immunoglobulins from human sera known to be positive for anti-HIV antibodies. Reactive peptoids were then re-synthesized and rigorously evaluated in plate-based ELISAs. Four peptoids showed very good, and one showed excellent, properties for establishing a sero-diagnosis of HIV. These results demonstrate the feasibility of constructing sero-diagnostic assays for infectious diseases from libraries of random molecular shapes. In this study we sought a proof-of-principle that we could identify a potential diagnostic antibody ligand biomarker for an infectious disease in a random combinatorial library of 100 million peptoids. We believe that this is the first evidence that it is possible to develop sero-diagnostic assays - for any infectious disease - based on screening random libraries of non-biological molecular shapes.
Subject(s)
Combinatorial Chemistry Techniques/methods , HIV Antibodies/blood , HIV Infections/diagnosis , Peptide Library , Peptoids/chemistry , Peptoids/immunology , Biomarkers/blood , Enzyme-Linked Immunosorbent Assay , HIV Antibodies/immunology , HIV Infections/immunology , Humans , Ligands , Peptoids/chemical synthesisABSTRACT
Strategies to limit life-long dependence on antiretroviral therapy (ART) are needed. We randomized 81 human immunodeficiency virus (HIV)-infected subjects to 4 interventional arms involving continued ART plus ALVAC vCP1452 (or placebo) with or without interleukin (IL)-2 infusions. Viral load rebound 12 weeks after ART interruption was then analyzed to assess immune control. Fifty-two subjects reached the study end point. ALVAC recipients had 0.5 log(10) lower virologic rebounds (P=.033). IL-2 plus vaccine boosted CD4(+) T cell counts (P<.001) but did not diminish viral rebound. Significant changes were not detected for HIV-specific lymphoproliferative responses in any arm. This exploratory protocol provides useful clinical data for future therapeutic immunization trial design.